This company listing is no longer active
Resumen de acción ACGN
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 2 riesgos adicionales
Competidores de Aceragen, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$16.00 |
| 52 Week Low | US$0.36 |
| Beta | 1.14 |
| 1 Month Change | -48.99% |
| 3 Month Change | -76.54% |
| 1 Year Change | -95.55% |
| 3 Year Change | -98.96% |
| 5 Year Change | -99.78% |
| Change since IPO | -100.00% |
Noticias y actualizaciones recientes
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29Rentabilidad de los accionistas
| ACGN | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -11.6% | 0.5% | -0.7% |
| 1Y | -95.5% | 1.2% | 22.8% |
Rentabilidad vs. Industria: ACGN underperformed the US Biotechs industry which returned 6.3% over the past year.
Rentabilidad vs. Mercado: ACGN underperformed the US Market which returned 4.2% over the past year.
Volatilidad de los precios
| ACGN volatility | |
|---|---|
| ACGN Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: ACGN's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: ACGN's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1989 | 26 | John Taylor | www.aceragen.com |
Resumen de fundamentos de Aceragen, Inc.
| Estadísticas fundamentales de ACGN | |
|---|---|
| Capitalización bursátil | US$3.20m |
| Beneficios(TTM) | -US$41.05m |
| Ingresos (TTM) | US$7.33m |
0.4x
Ratio precio-ventas (PS)-0.1x
Ratio precio-beneficio (PE)¿Está ACGN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ACGN | |
|---|---|
| Ingresos | US$7.33m |
| Coste de los ingresos | US$15.40m |
| Beneficio bruto | -US$8.06m |
| Otros gastos | US$32.98m |
| Beneficios | -US$41.05m |
Últimos beneficios comunicados
Mar 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -4.88 |
| Margen bruto | -110.00% |
| Margen de beneficio neto | -559.86% |
| Ratio deuda/patrimonio | 1.3% |
¿Cómo se ha desempeñado ACGN a largo plazo?
Ver rendimiento histórico y comparativa